Melanoma News Today

    Skip to content
    • Home
    • About Melanoma
    • Keytruda (Pembrolizumab)
    • Melanoma Clinical Trials
    • Contact Us
    May 12, 2016May 12, 2016

    Bim Marker May Predict Success for Melanoma Immunotherapy

    News
    Mayo Clinic researchers have discovered that a potential marker called Bim may be a clue to overall survival in patients undergoing anti-PD-1 therapy. The team believes that measuring the Bim ... Read more
    May 10, 2016May 10, 2016

    New Compound Successfully Targets Mutation Linked to Melanoma and Lymphoma

    Melanoma, News
    A study has shown that a new compound, JQEZ5, may help to treat certain types of cancers, particularly lymphoma and melanoma. The article, published in the journal Nature Medicine, is titled “An oncogenic Ezh2 mutation induces ... Read more
    May 5, 2016May 5, 2016

    Gene Expression Test of Metastasis Risk in Melanoma Patients Validated in Independent Study

    Melanoma, News
    An independent study of Castle Biosciences’ DecisionDx-Melanoma gene expression profile test, used to identify the risk of metastasis in patients with stage 1 or 2 cutaneous melanoma, verified the accuracy ... Read more
    April 28, 2016April 28, 2016

    Nivolumab (Opdivo) Seen in Clinical Trial to Improve Long-Term Survival in Advanced Melanoma Patients

    News
    Bristol-Myers Squibb’s nivolumab (Opdivo) has shown a robust five-year overall survival (OS) rate of 34 percent in heavily pretreated patients with metastatic melanoma, who had not received prior ipilimumab (Yervoy) therapy. The ... Read more
    April 26, 2016April 26, 2016

    Aging Influences Melanoma Response to Therapies, but Antioxidants Could Provide Answer

    News
    The risk of developing cancer increases with age as accumulated damage to the cells and chronic inflammation arise over time. In a new study published in Nature, an international team of ... Read more
    April 21, 2016April 21, 2016

    Melanoma Study in Mice Finds a Macrophage Group with Unusual Ability to Protect Against Cancer Progression

    News
    Massachusetts General Hospital researchers working in a mouse model of melanoma found that a specific type of immune cell — called subcapsular sinus (SCS) macrophages — forms a protective coat around lymph ... Read more
    April 19, 2016April 19, 2016

    Melanoma Research Alliance to Benefit from May 24 Fundraiser Sponsored by Leverage Finance Community

    News
    The Melanoma Research Alliance (MRA) will be the beneficiary of a May 24 fundraiser by the leveraged finance community to support continued research into better treatments and, possibly, a cure for the skin ... Read more
    April 12, 2016April 12, 2016

    Targeted Checkpoint Blocking Therapies Not Yet an Effective Melanoma Treatment, Cancer Expert Says

    News
    In a talk at the recent HemOnc Today’s Melanoma and Cutaneous Malignancies meeting, Christian Blank, group leader of the division of immunology at Netherlands Cancer Institute, presented his views of checkpoint blocking therapies. ... Read more
    April 5, 2016April 7, 2016

    Advanced Melanoma Combo Treatment, Opdivo/Yervoy, Gets a Positive Opinion from CHMP

    News
    The Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion supporting the approval of Bristol-Myers Squibb‘s Opdivo (nivolumab), combined with Yervoy (ipilimumab), to treat adult patients with advanced (unresectable or metastatic) melanoma. The CHMP opinion also added a statement to ... Read more
    March 31, 2016March 31, 2016

    Immunocore Recruits 1st Uveal Melanoma Patient in Phase I Trial of Biological Drug, IMCgp100

    News
    Immunocore announced it has recruited the first patient for its Phase I monotherapy clinical trial of IMCgp100, its lead product candidate to treat uveal melanoma. Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, ... Read more
    March 29, 2016March 29, 2016

    Melanoma Study in Mice Uses a Microneedle Patch System to Effectively Deliver Immunotherapy

    News
    Despite advances in melanoma treatment, mainly as a consequence of anti-PD-1 (aPD1) immunotherapy, the approach still needs improvement. Now, North Carolina State University and the University of North Carolina at Chapel Hill ... Read more
    March 24, 2016March 24, 2016

    Multiple Gene Mutations Predict Recurrence in Malignant Melanoma and Clinical Outcomes, Study Suggests

    News
    In a new study, researchers investigated whether molecular profiling could predict clinical outcomes, and found that patients with primary malignant melanoma are at a higher risk of recurrent disease if they present ... Read more
    March 22, 2016March 22, 2016

    Melanoma Cells’ Transition from Benign to Malignant Mapped, and Reversed, in Yale Lab

    News
    The mechanism by which benign melanoma cells change into malignant ones is greatly affected by the cells’ stiffness, as determined by the specific balance of two signaling pathways — which, in turn, can ... Read more
    March 17, 2016March 17, 2016

    myPath Melanoma Test Shows 90% Accuracy in 2nd Trial, Company Reports at USCAP 2016

    News
    Myriad Genetics, Inc., recently released positive data from a second and pivotal clinical validation trial of its myPath Melanoma test in a poster presentation at the 2016 USCAP Annual Meeting in Seattle, Washington. “There is significant emotional distress associated ... Read more
    March 15, 2016March 15, 2016

    Study Links Increased Risk of Melanoma to Use of Sildenafil

    News
    Researchers have found that sildenafil — a drug used to treat erectile dysfunction and pulmonary hypertension — is linked to an increased risk of melanoma by promoting cGMP-cGKI signaling cascade. The ... Read more
    March 10, 2016March 10, 2016

    Researchers Identify Gene Linked to Growth of Melanoma, Possibly Leading to New Treatments

    News
    Yale researchers have discovered a gene associated with melanoma and its growth, which could pave the way for new therapeutics. The study, “DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 ... Read more
    March 8, 2016May 17, 2016

    Blood Test May Reveal Early Signs of Skin Cancer Relapse

    News
    A recent study published in Cancer Discovery has revealed that a blood test may give early alerts of a relapse in advanced melanoma patients. The study, titled “Application of sequencing, liquid biopsies and patient-derived xenografts ... Read more
    March 3, 2016March 3, 2016

    Melanomas Often Diagnosed in People with a Limited Number of Skin Moles, Study Reports

    News
    Nevi, or skin moles, are strongly associated with melanoma. But recent findings revealed that most melanoma patients have few and no atypical moles, and thick melanomas in people under age 60 are more often found in ... Read more
    March 1, 2016March 1, 2016

    New Malignant Melanoma Target Discovered by Yale Researchers

    News
    Researchers at Yale Cancer Center have discovered a gene that has a dramatic impact on the growth of melanoma. Their observations, titled ”DNMT3b Modulates Melanoma Growth by Controlling Levels of ... Read more
    February 25, 2016February 25, 2016

    Study Finds Link Between Melanoma and Parkinson’s Disease, Researchers Say

    News
    Recent findings indicate there may be a link between Parkinson’s disease and melanoma, with family history and common genetic susceptibility as possible causes. The review is published in the journal Dermatologic Surgery ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another melanoma update.

    * indicates required

    Recent Melanoma Articles

    • clinical trial results

      Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

      June 8, 2017

    • DecisionDx-Melanoma prognosis test

      New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

      June 6, 2017

    • Biothera presents trial results

      Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

      June 1, 2017

    • melanomas that resist immune response

      Researchers Provide New Insights into Melanoma Immune Resistance

      May 30, 2017

    • nevus mole prognosis BGB324

      New Clinical Trial Underway for Treatment of Advanced Melanoma

      May 25, 2017

    You May Also Like…..

    Opdivo, Yervoy Combo Improved Survival in Advanced Melanoma Phase 3 Trial

    April 6, 2017

    Opdivo, Yervoy combination

    Researchers Link Alcohol Consumption to Risk of Developing Invasive Melanoma

    December 13, 2016

    Alcohol consumption and melanoma

    Expert Panel Recommends National Guidelines to Improve Melanoma Screening

    March 28, 2017

    melanoma screening guidelines
    Visit Melanoma News Today's profile on Pinterest.
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • clinical trial results

      Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

      June 8, 2017

    • DecisionDx-Melanoma prognosis test

      New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

      June 6, 2017

    • Biothera presents trial results

      Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

      June 1, 2017

    • melanomas that resist immune response

      Researchers Provide New Insights into Melanoma Immune Resistance

      May 30, 2017

    • About Melanoma News Today
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Melanoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.